CCR2 and lymphoma: In an in vivo study using lymphoma-grafted mice administered systemically, the CCR2 (which is a chemokine receptor) gene was targeted by siRNA, which inhibited its deposition in the sites of inflammation, by degrading the CCR2 mRNA in monocytes.